MA33751B1 - Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 - Google Patents

Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Info

Publication number
MA33751B1
MA33751B1 MA34869A MA34869A MA33751B1 MA 33751 B1 MA33751 B1 MA 33751B1 MA 34869 A MA34869 A MA 34869A MA 34869 A MA34869 A MA 34869A MA 33751 B1 MA33751 B1 MA 33751B1
Authority
MA
Morocco
Prior art keywords
orl
compounds
treatment
spirobridine
receptor antagonists
Prior art date
Application number
MA34869A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Alma Maria Jimenez-Aguado
Blanco Celia Lafuente
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Escribano Miguel Angel Toledo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33751B1 publication Critical patent/MA33751B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA34869A 2009-11-16 2012-05-14 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 MA33751B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27
PCT/US2010/056180 WO2011060035A1 (en) 2009-11-16 2010-11-10 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (1)

Publication Number Publication Date
MA33751B1 true MA33751B1 (fr) 2012-11-01

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34869A MA33751B1 (fr) 2009-11-16 2012-05-14 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (OSRAM)
EP (1) EP2501703B1 (OSRAM)
JP (1) JP5680101B2 (OSRAM)
KR (1) KR101363830B1 (OSRAM)
CN (1) CN102612520B (OSRAM)
AR (1) AR078863A1 (OSRAM)
AU (1) AU2010319581C1 (OSRAM)
CA (1) CA2796161C (OSRAM)
CO (1) CO6541545A2 (OSRAM)
CR (1) CR20130087A (OSRAM)
DK (1) DK2501703T3 (OSRAM)
DO (1) DOP2012000135A (OSRAM)
EA (1) EA020848B1 (OSRAM)
EC (1) ECSP12011902A (OSRAM)
ES (1) ES2435814T3 (OSRAM)
HN (1) HN2012001011A (OSRAM)
HR (1) HRP20130967T1 (OSRAM)
IL (1) IL219370A (OSRAM)
JO (1) JO2887B1 (OSRAM)
MA (1) MA33751B1 (OSRAM)
ME (1) ME01537B (OSRAM)
MX (1) MX2012005691A (OSRAM)
MY (1) MY160665A (OSRAM)
NZ (1) NZ600006A (OSRAM)
PE (1) PE20121430A1 (OSRAM)
PH (1) PH12012500969A1 (OSRAM)
PL (1) PL2501703T3 (OSRAM)
PT (1) PT2501703E (OSRAM)
RS (1) RS53018B (OSRAM)
SI (1) SI2501703T1 (OSRAM)
TW (1) TWI465453B (OSRAM)
UA (1) UA107943C2 (OSRAM)
WO (1) WO2011060035A1 (OSRAM)
ZA (1) ZA201202967B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ767139A (en) 2009-12-04 2022-08-26 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
WO2014053450A1 (de) 2012-10-02 2014-04-10 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
PL3589638T3 (pl) 2017-03-02 2021-09-27 Eli Lilly And Company Związki użyteczne do hamowania ror-gamma-t
EP3589637B1 (en) * 2017-03-02 2021-04-14 Eli Lilly and Company Compounds useful for inhibiting ror-gamma-t
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
EP3752508A1 (en) 2018-02-16 2020-12-23 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
AR123355A1 (es) 2020-08-26 2022-11-23 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
US20250171459A1 (en) * 2022-02-08 2025-05-29 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
AU1948601A (en) 1999-12-06 2001-06-12 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
ATE403429T1 (de) 2001-04-18 2008-08-15 Euro Celtique Sa Spiropyrazol-verbindungen
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
ATE396995T1 (de) 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
JP2005519921A (ja) * 2002-01-28 2005-07-07 ファイザー株式会社 Orl−1受容体リガンドとしてのn置換スピロピペリジン化合物
JPWO2003095427A1 (ja) 2002-05-10 2005-09-15 大正製薬株式会社 スピロ環化合物
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
MXPA05002622A (es) 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
BRPI0509307A (pt) * 2004-03-29 2007-09-04 Pfizer compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
PT2260042E (pt) 2008-03-27 2011-12-06 Gruenenthal Gmbh Derivados de ciclo-hexano espirocíclicos substituídos

Also Published As

Publication number Publication date
MY160665A (en) 2017-03-15
RS53018B (sr) 2014-04-30
EP2501703B1 (en) 2013-09-18
CA2796161A1 (en) 2011-05-19
NZ600006A (en) 2014-05-30
PL2501703T3 (pl) 2014-02-28
ME01537B (me) 2014-04-20
CN102612520A (zh) 2012-07-25
CO6541545A2 (es) 2012-10-16
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
HK1169988A1 (en) 2013-02-15
DK2501703T3 (da) 2013-10-14
PE20121430A1 (es) 2012-10-26
DOP2012000135A (es) 2012-08-15
CN102612520B (zh) 2015-04-08
KR101363830B1 (ko) 2014-02-14
IL219370A0 (en) 2012-06-28
CA2796161C (en) 2015-03-17
JP2013510859A (ja) 2013-03-28
US8232289B2 (en) 2012-07-31
UA107943C2 (xx) 2015-03-10
EP2501703A1 (en) 2012-09-26
MX2012005691A (es) 2012-06-13
EA201290352A1 (ru) 2012-10-30
SI2501703T1 (sl) 2013-11-29
AU2010319581C1 (en) 2014-05-15
CR20130087A (es) 2013-04-17
EA020848B1 (ru) 2015-02-27
IL219370A (en) 2015-01-29
KR20130026523A (ko) 2013-03-13
HRP20130967T1 (hr) 2013-11-22
WO2011060035A1 (en) 2011-05-19
PH12012500969A1 (en) 2013-01-07
PT2501703E (pt) 2013-11-26
ES2435814T3 (es) 2013-12-23
AU2010319581B2 (en) 2013-12-19
US20110118251A1 (en) 2011-05-19
AU2010319581A1 (en) 2012-06-07
TW201127841A (en) 2011-08-16
HN2012001011A (es) 2015-08-31
JP5680101B2 (ja) 2015-03-04
JO2887B1 (en) 2015-03-15
ECSP12011902A (es) 2012-07-31
AR078863A1 (es) 2011-12-07

Similar Documents

Publication Publication Date Title
MA33751B1 (fr) Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1
PT2501704E (pt) Compostos de espiropiperidina como antagonistas do receptor orl-1
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
WO2006029153A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
PH12012501640A1 (en) Novel compounds as opioid receptor modulators
WO2008112159A3 (en) Monocyclic anilide spirolactam cgrp receptor antagonists
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
PH12014502280A1 (en) Indole and indazole compounds that activate ampk
MY148544A (en) Pyridyl piperidine orexin receptor antagonists
DE602005020472D1 (de) Tricyclische anilid-spirohydantoin-cgrp-rezeptorantagonisten
JO3346B1 (ar) مواد مضادة C5aR
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MA33155B1 (fr) Composes organiques et leurs utilisations
MA31766B1 (fr) Composés organiques
ATE537153T1 (de) Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
ATE518852T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
CH707539A8 (fr) Alliage d'or rose pour pièce d'horlogerie.
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
GB2498268A (en) Silicone protectant compositions